A prospective clinical study showed that maintenance with 5-fluorouracil (5-FU) after the FOLFOX-4 regimen could improve the median PFS (5.9 months) and mOS (9.6 months) in advanced HER-2 negative GC patients [25]. Here, ERBB2 is linked to gastric cancer.